Search Results

BrainChild Bio’s lead asset BCB-276 is in pivotal development for diffuse intrinsic pontine glioma, a rare and fatal brain tumor that affects around 300 children in the U.S. every year.

Proposed Acquisition Valued at Approximately $15 Million Would Add an Established 50-State Telehealth Business, with over 90,000 clients, Focused on Peptides such as GLP-1 Weight Management, Hormone Health, Longevity and Sexual Wellness Key Highlights: • Target generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 (unaudited, as provided by Target management) and is cash-flow positive • Proposed purchase price of approximately $15 million, payable in cash and KALA stock; the cash portion is expected to be funded from existing balance sheet resources • Founded in 2023; LegitScript-certified, NABP-accredited platform serving clients in all 50 states; more than 90,000 clients served since inception • 45-day due diligence period expected to conclude in November 2026; definitive agreements and closing targeted for late 2026 or early 2027

Treos Bio, a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, said investigators will present new results from a phase 2 trial of the company’s lead product candidate PolyPEPI1018 in combination with Roche’s PD-L1 inhibitor atezolizumab in patients with late-stage microsatellite stable metastatic colorectal cancer at the 2024 ASCO Annual Meeting.

Treos Bio Limited announced the presentation of results from its phase 2 OBERTO-301 study of the company’s lead product candidate, PolyPEPI1018, in combination with atezolizumab in patients with late-stage microsatellite stable metastatic colorectal cancer at the 2024 American Society of Clinical Oncology Annual Meeting.